<?xml version="1.0" encoding="UTF-8"?>
<p id="par0035">The fact that the concentration with which chloroquine managed to inhibit 90% of the pathogen, of 6.90 μM, was previously achieved in patients with rheumatoid arthritis at doses of 500 mg
 <xref rid="bib0155" ref-type="bibr">
  <sup>8</sup>
 </xref> motivated the start of several clinical trials in China, the preliminary results of which were published on 
 <bold>19th February</bold> in a review article that stated that this drug had shown benefits in 100 patients, presumably managing to prevent the exacerbation of pneumonia, improve lung CT images, promote virus suppression and shorten the duration of the disease without producing any serious adverse reaction.
 <xref rid="bib0160" ref-type="bibr">
  <sup>9</sup>
 </xref>
</p>
